HRSA on Friday warned Sanofi against implementing its planned rebate model for some of its outpatient drugs under the drug ...
A turbulent 2024 for Neurocrine is ending on a high note, after the biotech won FDA approval to treat congenital adrenal ...
Edgewise Therapeutics’ treatment candidate for several forms of muscular dystrophy has hit the primary endpoint in a ...
Biohaven reports BHV-1300's lowest dose reduced IgG by 60%+ in trial, below analysts' 70-80% target. Drug shows promise for ...
PureTech Health unveiled positive Phase 2b data on Monday for its idiopathic pulmonary fibrosis drug, which showed it can ...
Just days after winning FTC approval to take on three of Catalent’s facilities, Novo Nordisk said it is investing DKK 8.5 ...
Bristol Myers drops cell therapy pacts with Immatics, Century as part of portfolio review
Bristol Myers Squibb is ending a pair of cell therapy collaborations with Immatics and nixing a separate agreement with ...
FTC approves Novo Holdings' $16.5B Catalent acquisition. Deal includes selling 3 facilities to Novo Nordisk for $11B, despite ...
Organon won a label expansion for the steroid-free topical cream it picked up from its October acquisition of Dermavant.
Bicycle Therapeutics reports mixed data for zelenectide pevedotin in cancer trials, with 60% response rate in urothelial ...
Endpoints Weekly covers ASH conference highlights, FDA discussions on Moderna's RSV vaccine safety, Biosecure Act exclusion, and industry updates from biotech leaders.
The FDA is pushing back against claims that its safety restrictions for the abortion pill mifepristone are “onerous and ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results